Loading organizations...
Key people at nQ Medical Inc.
nQ Medical develops a Digital Biomarker Discovery Platform that leverages AI to analyze passive personal device interactions for phenotyping neurological diseases. This platform identifies early indicators, tracks disease progression with granularity, and assesses therapeutic intervention efficacy. Its applications span disorders like Alzheimer’s, Parkinson’s, ALS, and conditions such as Long COVID.
Founded in 2016 by Richie Bavasso and Mark Pascarella, nQ Medical emerged from research with MIT, aiming to transform neurocognitive and neuromotor disorder management. The founders recognized the potential of continuously collected digital biomarkers from everyday device use to provide objective insights into brain health, driving the company’s inception and technical approach.
The company’s platform serves health systems and neurology practices, with its NeuroCare service model designed to deliver specialized neurological care. nQ Medical envisions a future where brain health monitoring is accessible and pervasive, democratizing high-quality neurological services through extended virtual care and reaching underserved populations.
nQ Medical, Inc. is a Cambridge, MA–based neurotechnology company that develops AI‑powered digital biomarkers by passively analyzing everyday personal device interactions to detect and track neurological and neurocognitive disorders. [1][4]
High-Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
If you’d like, I can (a) summarize their regulatory filings and Breakthrough Designation details, (b) map potential competitors and comparators in digital neurology, or (c) produce a short investor‑style SWOT analysis—tell me which you prefer.
Key people at nQ Medical Inc.